Logos Global Management LP Has $11.32 Million Position in enGene Holdings Inc. (NASDAQ:ENGN)

Logos Global Management LP grew its holdings in enGene Holdings Inc. (NASDAQ:ENGN) by 50.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,200,000 shares of the company’s stock after purchasing an additional 400,000 shares during the quarter. enGene comprises about 0.9% of Logos Global Management LP’s investment portfolio, making the stock its 27th largest position. Logos Global Management LP owned 2.72% of enGene worth $11,316,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. SR One Capital Management LP acquired a new position in enGene in the second quarter worth $4,715,000. Janus Henderson Group PLC acquired a new position in shares of enGene during the first quarter valued at $17,095,000. Altitude Crest Partners Inc. acquired a new position in shares of enGene during the first quarter valued at $2,039,000. Omega Fund Management LLC acquired a new position in shares of enGene during the fourth quarter valued at $10,441,000. Finally, BVF Inc. IL acquired a new position in shares of enGene during the fourth quarter valued at $20,777,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Stock Down 11.1 %

Shares of enGene stock opened at $6.41 on Tuesday. enGene Holdings Inc. has a 1 year low of $4.94 and a 1 year high of $43.00. The business has a 50-day moving average of $7.24 and a two-hundred day moving average of $11.03. The company has a market capitalization of $283.10 million, a P/E ratio of -3.86 and a beta of -0.68. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 42.80.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.05. As a group, equities analysts predict that enGene Holdings Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

ENGN has been the topic of several research reports. Oppenheimer initiated coverage on enGene in a research note on Wednesday, August 28th. They set an “outperform” rating and a $30.00 price target on the stock. Morgan Stanley reissued an “overweight” rating and issued a $40.00 target price on shares of enGene in a research note on Wednesday, September 11th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $33.67.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.